• Heart rate, B/P; severe bradycardia may occur with amiodarone used concurrently
• Severe renal disease/GFR <30 mL/min/1.73 m^2; monitor BUN, creatinine
• Closer monitoring in geriatric patients; may develop renal, cardiac symptoms more rapidly

Anemia:
• monitor Hgb/Hct if anemia is suspected
• **Pregnancy/breastfeeding:** the use of sofosbuvir/velpatasvir in combination with ribavirin is contraindicated in pregnant women and in the male partners of women who are pregnant; birth defects and/or death of the fetus may result. May cause male-mediated teratogenicity and is contraindicated for use during pregnancy, in females who may become pregnant, or in men whose female partners are pregnant. Patients and their partners are required to use two reliable forms of effective contraception during treatment and for 6 mo after use of these combination therapies. Females must also undergo a pregnancy test immediately before initiation of therapy, monthly during therapy, and for 6 mo post-therapy. To monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment and for 6 mo following cessation of treatment, health care providers are encouraged to report any cases to the Ribavirin Pregnancy Registry, 800-593-2214. For patients who are also infected with HIV and taking concomitant antiretrovirals, an Antiretroviral Pregnancy Registry is available at 800-258-4263; do not breastfeed

Evaluate:
• Decreased symptoms of chronic hepatitis C

Teach Patient/Family:
• That optimal duration of treatment is unknown; that product is not a cure, that transmission to others may still occur
• To avoid use with other products unless approved by prescriber
• Not to stop abruptly unless directed, worsening of hepatitis may occur; to keep in original container
• **Pregnancy/breastfeeding:** teach patients that they and their partners are required to use two reliable forms of effective contraception during treatment and for 6 mo after use of these combination therapies; that pregnancy tests are needed immediately before initiation of therapy, monthly during therapy, and for 6 mo post-therapy; not to breastfeed

Black Box Warning: Hepatitis exacerbation: report to provider immediately signs of liver toxicity (yellow eyes or skin, fatigue, weakness, loss of appetite, nausea, vomiting, or light-colored stools)

solifenacin (Rx)

(sol-i-fen′a-sin)

VESIcare

Func. class.: Urinary antispasmodic, anticholinergic

Chem. class.: Antimuscarinic

Do not confuse:
Vesicare/Vesanoid

ACTION: Relaxes smooth muscles in urinary tract by inhibiting acetylcholine at postganglionic sites

USES: Overactive bladder (urinary frequency, urgency, incontinence)

CONTRAINDICATIONS: Hypersensitivity, uncontrolled closed-angle glaucoma, urinary retention, gastric retention
Precautions: Pregnancy, breastfeeding, children, geriatric patients, renal/hepatic disease, controlled closed-angle glaucoma, bladder outflow obstruction, GI obstruction, decreased GI motility, history of QT prolongation

DOSAGE AND ROUTES

• **Adult: PO** 5 mg/day, max 10 mg/day

Renal/hepatic dose
• **Adult: PO** (Child-Pugh B) max 5 mg/day; CCr ≤30 mL/min, 5 mg/day